Aclaris Therapeutics: bosakitug misses Phase 2 goals
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aclaris Therapeutics, Inc. (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis did not achieve its primary endpoint—percent change from baseline in Eczema Area and Severity Index score at Week 24—or its secondary endpoints. Pharmacodynamic results showed robust target engagement of TSLP and downregulation of immune-activation biomarkers including Th1, Th2 and Th17; bosakitug was generally well tolerated.
Aclaris initiated the randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib for moderate-to-severe lichen planus. The study is designed for approximately 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts, testing two dose levels against placebo; the FDA granted modzatinib Fast Track Designation. Top-line results from the oral erosive cohort are expected in the second half of 2027.
Aclaris completed IND-enabling studies for ATI-9494 and expects to file an IND in the fourth quarter of 2026, with a Phase 1 trial expected to start in the first quarter of 2027. It intends to start a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointADMIRATION missed primary and secondary endpoints in atopic dermatitis.
8-K Event Classification
Key Figures
Key Terms
Eczema Area and Severity Index (EASI) medical
pharmacodynamic medical
target engagement technical
Fast Track Designation regulatory
Oral Disease Severity Score (ODSS) medical
double-blind, placebo-controlled technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Aclaris ACRS's bosakitug Phase 2 results?
What are the primary endpoints in Aclaris ACRS's modzatinib ALPHA trial?
When does Aclaris expect modzatinib ALPHA trial results?
AI-generated analysis. How Rhea-AI works. Not financial advice.



